Evaluation of tuberculosis infection control measures in China's designated medical institutions: a comparative analysis of 2014 and 2022

中国指定医疗机构结核病感染控制措施评价:2014年与2022年对比分析

阅读:1

Abstract

OBJECTIVE: To assess the implementation of infection prevention and control (IPC) measures in municipal and higher-level tuberculosis (TB)-designated medical institutions and to identify areas for improvement by comparing data from 2014 and 2022. METHODS: This study compared infection control measures using data from 47 TB-designated medical institutions that participated in both the 2014 and 2022 national surveys. Implementation rates of administrative, environmental and respiratory protection measure were compared. RESULTS: A total of 47 institutions were analyzed, including 20 provincial institutions (42.6%) and 27 municipal institutions (57.4%). Overall infection control performance in 2022 was high and consistent across regions, levels, and grades. Significant improvements from 2014 to 2022 were observed in: dedicated pathways for patients/staff (80.9% vs. 97.9%, 17.0% increase), separate wards for smear-positive/smear-negative patients (63.8% vs. 87.2%, 23.4% increase), separate wards for drug-resistant/non-resistant patients (74.5% vs. 95.7%, 21.2% increase), and use of medical protective mask by staff (70.2% vs. 95.7%, 25.5% increase) (all P < 0.05). The use of air purification/filtration also increased significantly (14.9% vs. 57.4%, 42.5% increase, P < 0.001), with over 90% of institutions adopting natural ventilation and ultraviolet germicidal irradiation. CONCLUSION: Significant improvements in IPC measures were achieved between 2014 and 2022, particularly in administrative controls. However, further efforts are needed to standardize ward zoning management and ensure more equitable resource allocation across regions and institution levels.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。